Advanced Filter

Filter by Group

Filter by Market Availability

Displaying drugs 15051 - 15075 of 15134 in total
Experimental
Experimental
Experimental
Experimental
PRLX 93936 is selectively toxic to cancer cells.
Investigational
Experimental
GO-203-2C is under investigation in clinical trial NCT02204085 (A Phase I/II Trial of the MUC1 Inhibitor, GO-203-2C in Patients With Relapsed or Refractory Acute Myeloid Leukemia).
Investigational
Matched Iupac: … hydroxypentylidene]amino}-1-hydroxypentylidene]amino}-1-hydroxyhexylidene]amino}-3-(C-hydroxycarbonimidoyl)propanoic acid
Experimental
Experimental
Gantacurium chloride is a new, investigational, non-depolarizing ultra-short acting neuromuscular blocker. It is being developed by Avera Pharmaceuticals.
Investigational
XL019 is a selective inhibitor of the cytoplasmic tyrosine kinase JAK2. An IND for XL019 was filed by Exelixis in May 2007.
Investigational
Experimental
Doramapimod is a P38 MAP kinase inhibitor.
Investigational
Displaying drugs 15051 - 15075 of 15134 in total